Multiple myeloma:: Increase of the effectiveness of Velcade® (Bortezomib) through combination therapy

被引：0
|
作者：
Aschoff, K
机构：
来源：
TRANSFUSION MEDICINE AND HEMOTHERAPY | 2005年 / 32卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：284 / 284
页数：1
相关论文
共 50 条
  • [31] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
    Richardson, Paul G.
    Weller, Edie
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raje, Noopur S.
    Avigan, David E.
    Xie, Wanling
    Ghobrial, Irene M.
    Schlossman, Robert L.
    Mazumder, Amitabha
    Munshi, Nikhil C.
    Vesole, David H.
    Joyce, Robin
    Kaufman, Jonathan L.
    Doss, Deborah
    Warren, Diane L.
    Lunde, Laura E.
    Kaster, Sarah
    DeLaney, Carol
    Hideshima, Teru
    Mitsiades, Constantine S.
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (05) : 679 - 686
  • [32] Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma
    Jagannath, S
    Durie, BGM
    Wolf, J
    Camacho, E
    Irwin, D
    Lutzky, J
    McKinley, M
    Gabayan, E
    Mazumder, A
    Schenkein, D
    Crowley, J
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) : 776 - 783
  • [33] Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
    Yesilaltay, Alpay
    Muz, Dilek
    Erdal, Berna
    Bilgen, Turker
    Batar, Bahadir
    Turgut, Burhan
    Topcu, Birol
    Yilmaz, Bahar
    Avci, Burcu Altindag
    PATHOGENS, 2024, 13 (01):
  • [34] Improving the assessment of peripheral neuropathy in patients receiving bortezomib (velcade) treatment for multiple myeloma
    O'Hara, K.
    Bloodworth, C.
    Rose, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 153 : 38 - 38
  • [35] Prognostic impact of unfavorable cytogenetic abnormalities in multiple myeloma patients treated by Bortezomib (Velcade)
    Nemec, P.
    Greslikova, H.
    Zaoralova, R.
    Filkova, H.
    Kuglik, P.
    Oltova, A.
    Pour, L.
    Adam, Z.
    Krivanova, A.
    Krejci, M.
    Hajek, R.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 165 - 165
  • [36] Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma
    Jimenez-Zepeda, Victor H.
    Reece, Donna E.
    Trudel, Suzanne
    Chen, Christine
    Tiedemann, Rodger
    Kukreti, Vishal
    LEUKEMIA & LYMPHOMA, 2013, 54 (03) : 555 - 560
  • [37] Introducing Self Administration of Bortezomib (Velcade) to Myeloma Patients
    Burton, T.
    Bygrave, C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 15 - 15
  • [38] Complete remission of multiple myeloma associated IgA pemphigus after therapy with bortezomib (Velcade), cyclophosphamide and dexamethasone: Case report
    Szturz, P.
    Adam, Z.
    Feit, J.
    Krejci, M.
    Pour, L.
    Vasku, V.
    Cermakova, Z.
    Hajek, R.
    Mayer, J.
    ONKOLOGIE, 2010, 33 : 248 - 249
  • [39] Introducing Self Administration of Bortezomib (Velcade) to Myeloma Patients
    Burton, Tanya
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E349 - E350
  • [40] Combination therapy with bortezomib(Velcade®), Doxil®, and dexamethasone(VDD) in newly diagnosed myeloma:: Updated results of phase II clinical trial
    Jakubowiak, A.
    Al-Zoubi, A.
    Kendall, T.
    Khaled, Y.
    Mineishi, S.
    Hari, M.
    Kaminski, M.
    Soengas, M.
    Talpaz, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 180 - 181
12345